Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down – Should You Sell?

Bio-Rad Laboratories, Inc. (NYSE:BIO.B)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $277.00, but opened at $257.71. Bio-Rad Laboratories shares last traded at $257.71, with a volume of 115 shares.

Bio-Rad Laboratories Trading Down 13.7%

The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37. The business’s 50 day moving average price is $276.55 and its 200-day moving average price is $295.43. The firm has a market capitalization of $6.98 billion, a price-to-earnings ratio of 42.58 and a beta of 0.96.

Bio-Rad Laboratories (NYSE:BIO.B) last issued its quarterly earnings results on Thursday, April 30th. The company reported $1.89 earnings per share (EPS) for the quarter. Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of innovative products and systems that serve the life science research and clinical diagnostics markets. The company operates through two primary segments: Life Science, which delivers instruments, consumables and software for research applications, and Clinical Diagnostics, which offers quality control materials and reagent systems for blood typing, immunology and molecular testing. Bio-Rad’s product portfolio supports a wide range of applications, including protein analysis, gene expression, cell biology and digital PCR.

In the Life Science segment, Bio-Rad develops and markets technologies such as electrophoresis and imaging systems, chromatography instruments, laboratory consumables and software platforms that streamline experimental workflows.